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Abstract
Venous thromboembolism is a common disease that is associated with considerable
morbidity if left untreated. Recently, low-molecular-weight heparins (LMWHs) have been
evaluated for use in acute treatment of deep venous thrombosis and pulmonary embolism.
Randomized studies have shown that LMWHs are as effective as unfractionated heparin in
the prevention of recurrent venous thromboembolism, and are as safe with respect to the
occurrence of major bleeding. A pooled analysis did not show substantial differences among
different LMWH compounds used, but no direct comparison of the different LMWHs is
currently available. Finally, in patients with pulmonary embolism, there is a relative lack of
large studies of daily practice. It could be argued that large prospective studies, in patients
who were treated with LMWHs from the moment of diagnosis, are needed.
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Introduction
Venous thromboembolism is a relatively common disease,
and may result in death. Its average annual incidence has
been estimated at 48 per 100000 for deep venous throm-
bosis and 23 per 100000 for pulmonary embolism [1].
The clinical significance of venous thromboembolism is
not only because of the risk of death from pulmonary
embolism, but also because of the high risk of recurrent
events, the occurrence of subsequent morbidity such as
the post-thrombotic syndrome, and the consequent eco-
nomic impact caused by the high rate of hospitalization.
Since the early 1960s, anticoagulant therapy has been
proven to be pivotal in the treatment of venous throm-
boembolism. With the exception of massive pulmonary
emboli (occurring in <5% of patients who present with
pulmonary embolism, in whom thrombolytic therapy should
be considered), treatment of established deep venous
thrombosis and pulmonary embolism is essentially identi-
cal, and includes the administration of heparin for 5–10
days, and oral anticoagulants for at least 3 months [2].
Until recently, unfractionated heparin was the treatment
of choice. It can be administered by continuous intra-
venous infusion, starting with a bolus of 5000 interna-
tional units (IU) followed by 30000–35000IU/day,
adjusted to achieve an activated partial thromboplastin
time (APTT) of 1.5–2.5 times the control. Alternatively,
after the intravenous bolus injection, unfractionated
heparin can be administered subcutaneously, with
twice daily injections of 15000–20000IU, which are
aimed at maintaining therapeutic levels of APTT.http://cvm.controlled-trials.com/content/1/2/102
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Careful laboratory monitoring is necessary in order to
maintain therapeutic plasma concentrations of heparin. In
fact, inadequate anticoagulation may be responsible for a
high number of recurrent venous thromboembolic events
[3]. It has been reported [4] that patients who receive
intravenous heparin without reaching the therapeutic
range within the first 24h may have a rate of recurrence as
much as 15 times higher than that in patients who had
heparin levels within the therapeutic range.
Unfractionated heparin has a number of limitations. Its
anticoagulant effect is unpredictable and varies consider-
ably among patients, depending on age, sex, body weight,
smoking status and renal function. This wide variability is
caused by heparin binding to acute-phase reactant pro-
teins, levels of which vary among normal individuals and
disease states. Before therapeutic plasma levels are
achieved, the binding to plasma proteins and to receptor
sites on the endothelium must be saturated. Moreover,
unfractionated heparin has further effects on haemostasis,
such as inhibition of platelet aggregation and augmenta-
tion of vessel wall permeability, which can significantly
enhance its potential to cause bleeding complications [5].
Finally, as many as 3% of treated patients will develop
heparin-induced thrombocytopenia [6].
Pharmacology and pharmacokinetics of LMWHs
LMWHs are obtained by chemical or enzymatic depolymer-
ization of porcine mucosal heparin preparations [7]. Their
reduced molecular weight (and thus their reduced number
of saccharide units) as compared with unfractionated
heparin leads to potential pharmacological and pharmacoki-
netic advantages over the parent compound, which result in
a greater clinical utility. Their antithrombotic activity is mainly
based on inactivation of factor Xa because of a reduced
ability to inactivate factor IIa when compared with unfrac-
tionated heparin. Moreover, the LMWHs do not bind to the
endothelium and have a lower affinity for plasma proteins.
This results in a more predictable bioavailability, a substan-
tially longer half-life, a stable dose/response relationship
when injected subcutaneously, and potentially a more
antithrombotic than haemorrhagic activity in comparison
with unfractionated heparin [8]. LMWHs also have minimal
interaction with platelets, and a reduced incidence of
heparin-induced thrombocytopenia has been observed [6].
Because of their properties, the LMWHs can be adminis-
tered subcutaneously in weight-adjusted, once or twice
daily doses without the need for laboratory monitoring.
Randomized trial data
Deep venous thrombosis
In the early 1990s, two randomized trials assessed the
efficacy and safety of the LMWHs in the treatment of
deep venous thrombosis. In a multicenter, double-blind
clinical trial, Hull et al [9•] randomized 219 patients to
receive unfractionated heparin administered intravenously
with an initial bolus of 5000IU followed by 30000IU or
40000IU every 24h (depending on the presence or
absence of risk factors for bleeding), and 213 patients to
receive a once daily, weight-adjusted dose of the LMWH
tinzaparin (175IU/kg). A nonsignificant reduction in the
incidence of recurrent venous thromboembolism (6.9% in
the standard heparin-treated group versus 2.8% in the
LMWH-treated group), a significant reduction in the rate
of major bleeding (5.0% versus 0.5%) and a significant
reduction in the rate of deaths (9.6% versus 4.7%) in
favour of the LMWH were observed.
In the same year, Prandoni et al [10] randomized 170
patients to a similar regimen of unfractionated heparin (a
bolus of 100IU/kg followed by a continous infusion of
35000IU every 24h, adjusted to achieve a target APTT of
1.5–2.0 times control), or to a twice daily, weight-adjusted,
subcutaneous administration of the LMWH nadroparin. The
results were similar to those reported by Hull et al [9•]: in
the LMWH group there was a nonsignificant reduction in
the rate of recurrent venous thromboembolism (14% in the
standard heparin-treated group versus 7% in the LMWH-
treated group), a nonsignificant reduction in major bleeding
(3.5% versus 1%) and a nonsignificant reduction in deaths
after 6 months of follow up (14% versus 7%).
Many other randomized trials subsequently compared the
LMWHs with standard heparin in the initial treatment of
acute proximal venous thrombosis, and their results were
evaluated in three different meta-analyses [11–13], which
concluded that LMWHs have greater efficacy and safety.
The most recent meta-analysis, including the most recent
studies [14•], found no difference between the unfraction-
ated heparin and LMWH (Table 1). The authors of that
report concluded that LMWHs have equal effectiveness to
that of unfractionated heparin in the prevention of recur-
rent episodes of venous thromboembolism, and equal
safety with respect to the occurrence of major bleeding.
Interestingly, a statistically significant reduction in total
mortality in patients treated with LMWHs was also found
in this meta-analysis. Also, a pooled analysis from the
selected trials showed no substantial differences among
the different LMWH products used in the studies, but, as
correctly recognized by those authors, no direct compar-
isons of the different LMWHs are actually available.
Finally, it is important to note that in all of the above-men-
tioned trials patients younger than 18 years, pregnant
patients and patients with severe renal failure were
excluded, and consequently the results of these studies
cannot be extrapolated to these specific patient groups.
The simple, unmonitored dosing system and the practical
administration of the LMWHs mean that these agents
could facilitate outpatient management of deep venous
thrombosis. Two large trials published in 1996 have clearly
demonstrated the safety and efficacy of such an approach.Current Controlled Trials in Cardiovascular Medicine    Vol 1 No 2 Ageno and Huisman
In the TASMAN study [15•], conducted in Europe, Aus-
tralia and New Zealand, 198 patients were randomized to
receive an adjusted-dose of intravenous unfractionated
heparin in the hospital, and 202 patients to receive a fixed,
weight-adjusted subcutaneous dose of the LMWH
nadroparin, which was administered at home, if it was con-
sidered possible. The rate of events was comparable in
the two groups with regard to recurrent venous throm-
boembolism (8.6 and 6.9%, respectively), major bleeding
(2.0 and 0.5%, respectively) and death (8.1 and 6.9%,
respectively). Importantly, the duration of hospitalization
was reduced by 67% from 8.1 days in the unfractionated
heparin group to 2.7 days in the LMWH group. In the
LMWH group, 75% of the patients were discharged
within 2 days or were not even admitted to the hospital.
The second study was carried out in Canada by Levine et
al [16•] (Table 2). The design of the trial and the sample
size were similar to those of the TASMAN study. There
were 253 patients randomized to the intravenous unfrac-
tionated heparin group, and 247 patients to the LMWH
enoxaparin group. The event rates of recurrent venous
thromboembolism and major bleeding did not reach statis-
tical significance and therefore it was concluded that the
LMWH enoxaparine was not inferior to unfractionated
heparin in the treatment of deep venous thrombosis. As in
the previous study, the time spent in the hospital was
remarkably reduced, from 6.5 days to 1.1 days, and 120
out of the 247 patients randomized to the LMWH were
never admitted to the hospital. This study and the TASMAN
study [15•] suggest the feasibility of a significant change in
the clinical management of patients presenting with deep
venous thrombosis, ie treating them at home with LMWH.
Two recently published reports from Canada [17,18] and
one from The Netherlands [19] suggest that more than
80% of patients with proximal deep venous thrombosis
can safely be treated from the first day with LMWH at
home without the need for hospitalization.
From pharmacokinetic data it has been observed that ther-
apeutic anti-Xa levels could be achieved over 24h when
LMWHs are administered once daily. Once daily dosing is
attractive because it may be more acceptable to the patient
and involves less nursing time. In one controlled study [20],
once daily nadroparin was shown to have equal efficacy
and safety as twice daily nadroparin. The primary end-point
of a combination of venous thromboembolism and mortality
was reported in 13 patients (4.1%) in the group that
received daily nadroparin and in 24 patients (7.2%) who
received twice daily nadroparin. Thus, an absolute differ-
ence of 3.1% (95% confidence interval –6.6% to 0.5%)
was observed in favour of the once daily therapy. Major
bleeding occurred in four patients both in the once daily
group (1.3%) and in the twice daily group (1.2%).
Pulmonary embolism
Because deep venous thrombosis and pulmonary
embolism are considered two manifestations of the same
disease – venous thromboembolism – the LMWHs have
also recently been tested in the setting of patients with
haemodynamically stable pulmonary embolism. Three trials
were published between 1997 and 2000: one was carried
out in a population of patients presenting with venous
thromboembolism, including submassive pulmonary
embolism [21]; one specifically in patients with submas-
sive pulmonary embolism [22]; and a third was conducted
Table 2
LMWH in the outpatient treatment of deep venous thrombosis
Adverse event LMWH Unfractionated heparin Risk reduction
Recurrent venous thromboembolism 4.45% 7.02% 37%
Major haemorrhage 1.00% 2.31% 57%
Death 4.55% 7.12% 36%
Pooled analysis of the studies of Koopman et al [15•] and Levine et al [16•].
Table 1
A meta-analysis comparing LMWH in the treatment of venous thromboembolism
Adverse event LMWH Unfractionated heparin RR (95% CI) P
Recurrent venous thromboembolism 96/2212 (4.3%) 115/2235 (5.1%) 0.85 (0.65–1.12) 0.20
Major haemorrhage 33/2212 (1.5%) 57/2235 (2.5%) 0.63 (0.37–1.05) 0.08
Total mortality 98/2006 (4.9%) 132/2027 (6.5%) 0.76 (0.59–0.98) 0.03
CI, confidence interval; RR, relative risk. Data from Dolovich et al [14•].in patients admitted for deep venous thrombosis who also
had objectively documented pulmonary embolism [23].
The COLUMBUS trial [21] was an international, random-
ized, open-label study that enrolled 1021 patients present-
ing with acute symptomatic deep venous thrombosis,
pulmonary embolism, or both. Patients were randomly
assigned to one of two groups. One group receive the
LMWH reviparin administered subcutaneously twice daily
at fixed, weight-adjusted doses (6300 anti-Xa units if body
weight was more than 60kg, 4200 anti-Xa units if body
weight was between 46 and 60kg, and 3500 units for a
body weight between 35 and 45kg). The other group
received unfractionated heparin administered intra-
venously in a 5000IU bolus followed by a dose of
1250IU/h, adjusted to achieve an APTT range between
60 and 85s. Home treatment was encouraged for patients
assigned to reviparin. Only 12 patients were excluded
because thrombolytic therapy was planned, and 271
patients with pulmonary embolism were included in the
study. The total rate of recurrences in the subgroup with
pulmonary embolism was comparable to that of the group
of patients with deep venous thrombosis (5.9% versus
4.8%, respectively), and was also similar in the two treat-
ment groups (5.8% in the reviparin group versus 6.0% in
the unfractionated heparin group). There were six
episodes of fatal pulmonary embolism (2.2%) during the 3
months of follow up, all of which occurred in the subgroup
of 271 patients enrolled with pulmonary embolism.
The THÉSÉE study [22] was a randomized, multicenter,
open-label trial. A total of 612 patients presenting with
symptomatic pulmonary embolism were assigned to
receive the LMWH tinzaparin administered subcuta-
neously at a once daily dose of 175 anti-Xa units/kg body
weight, or to receive unfractionated heparin administered
intravenously with an initial bolus of 50IU/kg followed by
an initial dose of 500IU/kg, adjusted to achieve therapeu-
tic levels of the APTT between 2 and 3 times the control
value. After 8 days, the occurrence of events included in
the primary outcome (recurrent venous thromboembolism,
major bleeding or death) was similar in the two treatment
groups: 2.9% in the unfractionated heparin group and
3.0% in the tinzaparin group. After 90 days this similarity
remained, with a 7.1% and 5.9% incidence in the unfrac-
tionated heparin and tinzaparin groups, respectively. There
was a 1.0% rate of fatal pulmonary emboli in both groups.
The study by Hull et al [23] included a subpopulation of an
earlier trial [9•] with objectively documented pulmonary
embolism with underlying deep venous thrombosis.
Patients were assigned to the LMWH tinzaparin, adminis-
tered, as in the previous study, subcutaneously in a once
daily fixed dose of 175 anti-Xa units/kg of body weight, or
to unfractionated heparin administered intravenously with
an initial bolus of 5000IU followed by a continuous infusion
of 40320IU/24h (or 29760IU/24h for those patients with
risk factors for bleeding), which was adjusted to achieve a
therapeutic APTT range between 1.5 and 2.5 times the
control value. Of the originally included 432 patients with
deep venous thrombosis, 200 had high-probability perfu-
sion lung scan findings and were included in this study.
Only 28 (14%) had presented with symptoms of pul-
monary embolism. There were no recurrent episodes of
venous thromboembolism in the group of patients treated
with tinzaparin, and seven new episodes (four pulmonary
embolisms) in the unfractionated heparin group (95% con-
fidence interval for the difference 1.9% to 11.7%;
P=0.01). Death occurred in 6.2% and 8.7% of patients,
respectively; only in one patient (in the unfractionated
heparin group) was death related to pulmonary embolism.
The LMWHs are currently considered a potentially valid
alternative to unfractionated heparin in the treatment of
pulmonary embolism in patients whose clinical condition
is stable. One might argue that there is a need for more
clinical studies, involving large groups of unselected
patients, presenting with clinically suspected pulmonary
embolism, who were treated with LMWHs from the
moment of diagnosis.
Conclusion
LMWHs have replaced unfractionated heparin in the initial
treatment of patients with deep venous thrombosis. Numer-
ous well-designed clinical trials have demonstrated that
LMWHs are as effective and safe as unfractionated heparin
and, because no laboratory control is needed, they are the
initial treatment of choice for initiating out-of-hospital antico-
agulant treatment in patients with acute deep venous throm-
bosis. For patients with pulmonary embolism, LMWHs are a
potential alternative for unfractionated intravenous heparin.
Whether all patients with pulmonary embolism can be
treated at home from the first day with LMWHs must be
assessed in prospective follow-up studies.
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